Global Rheumatoid Arthritis Therapeutics Market Report and Forecast 2023-2031

Global Rheumatoid Arthritis Therapeutics Market Report and Forecast 2023-2031
Global Rheumatoid Arthritis Therapeutics Market Outlook
The value of the global rheumatoid therapeutics market was USD 28.21 billion in 2022, driven by the increasing prevalence of rheumatoid arthritis across the globe. The market is expected to grow at a CAGR of 4.60% during the forecast period of 2023-2031 to reach value of USD 42.28 billion by 2031.

Rheumatoid Arthritis Therapeutics: Introduction

Rheumatoid arthritis (RA) is a chronic autoimmune disorder that primarily affects the joints. It occurs when the immune system mistakenly attacks the body's own tissues, leading to inflammation and joint damage. RA can cause pain, swelling, stiffness, and loss of function in the joints, as well as fatigue and other systemic symptoms. It is estimated that around 1% of the world's population is affected by RA, with women being more likely to develop the disease than men.

There is currently no cure for RA, but there are several types of medications that can help manage the symptoms and slow the progression of the disease. These include nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), biologic agents, and corticosteroids. Treatment is typically tailored to the individual patient and may involve a combination of medications, as well as physical therapy and other supportive measures. Ongoing research is focused on developing more effective treatments for RA, as well as gaining a better understanding of the underlying mechanisms of the disease.

Rheumatoid Arthritis Therapeutics Application and Uses
Rheumatoid arthritis (RA) therapeutics are used to treat rheumatoid arthritis, which is a chronic autoimmune disorder that causes inflammation in the joints, leading to pain, stiffness, and swelling. The application and uses of RA therapeutics include:

• Reducing inflammation: The main objective of RA therapeutics is to reduce inflammation in the joints, which helps alleviate pain and stiffness. This is achieved through the use of disease-modifying anti-rheumatic drugs (DMARDs) and biologic agents
• Slowing down joint damage: RA therapeutics also aim to slow down the progression of joint damage by preventing the immune system from attacking the joints. DMARDs and biologic agents are effective in achieving this goal
• Relieving pain: Pain relief is an important aspect of RA therapeutics. Nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids are commonly used to relieve pain and inflammation
• Improving physical function: RA can limit physical function due to joint pain and stiffness. Physical therapy and exercise can help improve physical function and reduce pain
• Preventing complications: RA therapeutics can also help prevent complications such as anaemia, osteoporosis, and cardiovascular disease, which can occur as a result of the disease or its treatment

Overall, RA therapeutics aim to improve the quality of life for individuals with rheumatoid arthritis by reducing pain, inflammation, and joint damage, and improving physical function.

Global Rheumatoid Arthritis Therapeutics Market Segmentations

Market Breakup by Product Type

• Biologics

Non-Biologics

• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
• Synthetic Disease-Modifying Antirheumatic Drugs (SDMARDs)
• Others

Market Breakup by Sales Type

• Prescription
• Over The Counter (OTC)
• Others

Market Breakup by Route of Administration

• Oral
• Parenteral

Market Breakup by Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online

Market Breakup by End User

• Hospitals and Clinics
• Research and Academic Laboratories
• Others

Market Breakup by Region

North America

• United States of America
• Canada

Europe

• United Kingdom
• Germany
• France
• Italy
• Others

Asia Pacific

• China
• Japan
• India
• ASEAN
• Australia
• Others

Latin America

• Brazil
• Argentina
• Mexico
• Others

Middle East and Africa

• Saudi Arabia
• United Arab Emirates
• Nigeria
• South Africa
• Others

Global Rheumatoid Arthritis Therapeutics Market Scenario

Rheumatoid arthritis is a chronic autoimmune disorder that affects the joints and can lead to joint deformity, loss of function, and disability. The increasing prevalence of rheumatoid arthritis is a key driver of the market, along with the rising aging population and the growing awareness about the condition.

The market is also being driven by the increasing availability of advanced biologic therapies and the development of innovative treatment approaches. However, the high cost of these therapies and the availability of biosimilars could pose a challenge to market growth
Geographically, North America is expected to dominate the market due to the high prevalence of rheumatoid arthritis in the region, as well as the presence of key market players. Europe is also expected to witness significant growth due to the increasing demand for advanced biologic therapies.

Key Players in the Global Rheumatoid Arthritis Therapeutics Market

The report gives an in-depth analysis of the key players involved in the global rheumatoid arthritis therapeutics market. The companies included in the market are as follows:

• Pfizer Inc
• Amgen Inc.
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche Ltd
• UCB S.A
• Gilead Sciences, Inc
• Boehringer Ingelheim GmbH
• Novartis International AG
• Regeneron Pharmaceuticals, Inc
• AbbVie
• Eli Lilly and Company

This product will be delivered within 5-7 business days.